Related Experiment Videos
Screening for glaucoma with frequency-doubling technology and Damato campimetry
N Yamada1, P P Chen, R P Mills
1Department of Ophthalmology, University of Washington, Seattle 98195-6485, USA.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|November 24, 1999
Summary
Frequency-doubling technology (FDT) perimetry demonstrated superior glaucoma detection compared to Damato campimetry in a public screening. FDT perimetry offered higher sensitivity and specificity with a faster test time.
Area of Science:
- Ophthalmology
- Medical Technology
- Public Health
Background:
- Glaucoma is a leading cause of irreversible blindness worldwide.
- Early detection through screening is crucial for managing glaucoma and preventing vision loss.
- Visual field testing plays a key role in glaucoma diagnosis and monitoring.
Purpose of the Study:
- To compare the effectiveness of frequency-doubling technology (FDT) perimetry and Damato campimetry for glaucoma detection during a public screening event.
- To evaluate the sensitivity and specificity of each perimetry method in identifying glaucoma.
Main Methods:
- A public glaucoma screening involved 240 subjects for FDT perimetry and 175 for Damato campimetry.
- Both tests were conducted alongside ophthalmologic examinations and Humphrey perimetry.
- Eyes were categorized as normal, ocular hypertensive, glaucoma suspect, or definite glaucoma.
Main Results:
- FDT perimetry achieved an area under the receiver operating characteristic curve of 0.925, with optimal sensitivity of 92% and specificity of 93%.
- Damato campimetry had an area under the curve of 0.883, with optimal sensitivity of 53% and specificity of 90%.
- FDT perimetry was significantly faster, averaging 1 minute per eye compared to 3 minutes for Damato campimetry.
Conclusions:
- Frequency-doubling technology perimetry proved superior to Damato campimetry for glaucoma screening in this study.
- FDT perimetry offers a more sensitive and specific, as well as a more time-efficient, method for public glaucoma screening.